Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 15mg/cap - lenalidomide 18,096mg - lenalidomide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 20mg/cap - lenalidomide 24,128mg - lenalidomide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 25mg/cap - lenalidomide 30,16mg - lenalidomide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 10mg/cap - lenalidomide 12,064mg - lenalidomide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 7.5mg/cap - lenalidomide 9,048mg - lenalidomide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 5mg/cap - lenalidomide 6,032mg - lenalidomide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

as grindeks, latvia krustpils iela 53, 1057 riga - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 2.5mg/cap - lenalidomide 3,016mg - lenalidomide

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, συστημικό - Ανοσοκατασταλτικά - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.